Digestive Diseases

Review Article

Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases

Schultz M. · Schölmerich J. · Rath H.C.

Author affiliations

Department of Internal Medicine I, University of Regensburg, Regensburg, Germany

Keywords: Inflammatory bowel diseaseAntibioticsProbiotics

Related Articles for ""
Dig Dis 2003;21:105–128
https://doi.org/10.1159/000073243

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review Article

Published online: October 24, 2003
Issue release date: 2003

Number of Print Pages: 24
Number of Figures: 3
Number of Tables: 2

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Abstract

Inflammatory bowel diseases (IBD), commonly referred to as Crohn’s disease and ulcerative colitis are chronic aggressive disorders which share many similarities concerning pathomechanism and clinical course, but have very distinct features. Both entities are mainly located in areas with high bacterial concentrations, such as the terminal ileum and cecum in Crohn’s disease and the rectum in ulcerative colitis. In recent years, overwhelming evidence accumulated, supporting the hypothesis that IBD are characterized by a genetically determined, overly aggressive immune response towards ubiquitous luminal antigens, especially commensal bacteria and their products. Trials in both human IBD and experimental colitis have demonstrated that broad-spectrum antibiotics may influence the course of ulcerative colitis and Crohn’s disease and antibiotics with narrow activity against the anaerobic fraction of the flora can prevent relapse in Crohn’s disease after surgically induced remission. Since relevant antibiotic strategies can be associated with some side effects, the ongoing research recently focused on alternative methods to modify the intestinal flora in patients with IBD. Clinical observations including few controlled trials, basic research, and animal studies have suggested a potential role for probiotic bacteria within the treatment regimens for IBD. However, the mode of action of these organisms is still largely unclear and in vitro studies are inconclusive. This review summarizes recent in vitro and in vivo data regarding the role of the intestinal microflora in the pathogenesis of chronic intestinal inflammation and possible therapeutic mechanisms of probiotic bacteria relevant to IBD. Furthermore, we will review clinical trials examining the efficacy of antibiotic and probiotic treatment strategies in IBD.

© 2003 S. Karger AG, Basel



Related Articles:

References

  1. Schultz M, Sartor RB: The contribution of bacterial flora to chronic intestinal inflammation; in Caprilli R (ed): Inflammatory Bowel Disease. Stuttgart, Schattauer, 1997, pp 17–24.
  2. Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski, Dallaire C, et al: A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn’s disease. The Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology 1997;112:1069–1077.
    External Resources
  3. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, et al: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277–2285.
    External Resources
  4. Onderdonk AB, Franklin ML, Cisneros RL: Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun 1981;32:225–231.
    External Resources
  5. Rath HC, Bender DE, Holt LC, Grenther T, Taurog JD, Hammer RE, et al: Metronidazole attenuates colitis in HLA-B27 / hβ2 microglobulin transgenic rats: A pathogenic role for anaerobic bacteria. Clin Immunol Immunopathol 1995;76:S45.
    External Resources
  6. Braat H, Dieleman LA, Sellon RK, Schultz M, Sartor RB: Effects of antibiotics on the initiation and perpetuation of colitis in the IL-10 KO mice. Gastroenterology 1998;114:G3853.
  7. Schölmerich J: Studien zur Rezidivprophylaxe des Morbus Crohn. Chirurg 1998;69:908–914.
    External Resources
  8. Metchnikoff E: The Prolongation of Life: Optimistic Studies. London, Heinemann, 1907, pp 161–183.
  9. Lilly DM, Stilwell RH: Probiotics: Growth promoting factors produced by microorganisms. Science 1965;47:747–748.
  10. Dunne C, Murphy L, Flynn S, O’Mahony L, O’Halloran S, Feeney M et al: Probiotics: from myth to reality: Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 1999;76:279–292.
    External Resources
  11. Shanahan F: Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622–635.
    External Resources
  12. Gorbach SL: Probiotics and gastrointestinal health. Am J Gastroenterol 2000;95:S2–S4.
    External Resources
  13. Marteau P, de Vrese M, Cellier CJ, Schrezenmeier J: Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73:430S–436S.
  14. Sartor RB, dela Cadena RA, Green KD, Stadnicki A, Davis SW, Schwab JH, et al: Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996;110:1467–1481.
    External Resources
  15. Lichtman SN, Sartor RB, Keku J, Schwab JH: Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990;98:414–423.
    External Resources
  16. Sartor RB: Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997;11:17–22.
    External Resources
  17. Sternberg EM, Young WS, Bernardini R, Calogero AE, Chrousos GP, Gold PW, et al: A central nervous system defect in biosynthesis of corticotropin- releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771–4775.
    External Resources
  18. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, Elson CO, et al: Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 1998;274:G544–G551.
  19. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH: Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 1994;107:1726–1735.
    External Resources
  20. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599–603.
    External Resources
  21. Beutler B: Autoimmunitiy and apoptosis: The Crohn’s connection. Immunity 2001;15:5–14.
    External Resources
  22. Hilsden RJ, Meddings JB, Sutherland LR: Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease. Gastroenterology 1996;110:1395–1403.
    External Resources
  23. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I: Intestinal permeability in patients with Crohn’s disease and their first degree relatives. Gut 1992;33:320–323.
    External Resources
  24. Hollander D: Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1999;1:410–416.
    External Resources
  25. Hobson CH, Butt TJ, Ferry DM, Hunter J, Chadwick VS, Broom MF: Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology 1988;94:1006–1013.
    External Resources
  26. von Ritter C, Sekizuka E, Grisham MB, Granger DN: The chemotactic peptide N-formyl methionyl-leucyl-phenylalanine increases mucosal permeability in the distal ileum of the rat. Gastroenterology 1988;95:651–656.
    External Resources
  27. Hermiston ML, Gordon JI: Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203–1207.
    External Resources
  28. Kent TH, Cardelli RM, Stammler FW: Small intestinal ulcers and intestinal flora in rats given indomethacin. Am J Pathol 1969;54:237–249.
    External Resources
  29. Reuter BK, Davies NM, Wallace JL: Nonsteroidal anti-inflammatory drug enteropathy in rats: Role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997;112:109–107.
    External Resources
  30. Satoh H, Gurth PH, Grossman NI: Role of bacteria in gastric ulceration produced by indomethacin in the rat: Cytoprotective action of antibiotics. Gastroenterology 1983;84:483–489.
    External Resources
  31. Elliott SN, Buret A, McKnight W, Miller MSJ, Wallace JL: Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol 1998;275:G425–G432.
  32. Isolauri E, Majamaa H, Arvola T, Rantala I, Virtanen E, Arvilommi H: Lactobacillus casei strain GG reverses increased permeability induced by cow milk in suckling rats. Gastroenterology 1993;105:1643–1650.
    External Resources
  33. Gotteland M, Cruchet S, Verbeke S: Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther 2001;15:11–17.
    External Resources
  34. Adawi D, Ahrne S, Molin G: Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol 2001;70:213–220.
    External Resources
  35. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al: Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–1108.
    External Resources
  36. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–309.
    External Resources
  37. Madsen KL, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580–591.
    External Resources
  38. van de Merwe JP, Schroder AM, Wensinck F, Hazenberg MP: The obligate anaerobic faecal flora of patients with Crohn’s disease and their first-degree relatives. Scand J Gastroenterol 1988;23:1125–1131.
    External Resources
  39. Giaffer MH, Holdsworth CD, Duerden BI: The assessment of fecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 1991;35:238–243.
    External Resources
  40. Fabia R, Ar’Rajab A, Johansson ML, Andersson R, Willen R, Jeppsson B, et al: Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993;54:248–255.
    External Resources
  41. Hartley MG, Hudson MJ, Swarbrick ET, Hill MJ, Gent AE, Hellier MD, et al: The rectal mucosa-associated microflora in patients with ulcerative colitis. J Med Microbiol 1992;36:96–103.
    External Resources
  42. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Chron’s disease of the colon. Gut 2003;52:237–242.
    External Resources
  43. Ruseler-van Embden JG, Both-Patoir HC: Anaerobic gram-negative faecal flora in patients with Crohn’s disease and healthy subjects. Antonie van Leeuwenhoek 1983;49:125–132.
    External Resources
  44. Sartor RB: Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis and experimental intestinal inflammation; in Kirsner JB (ed): Inflammatory Bowel Disease. Baltimore, Williams & Wilkins, 1999, pp 153–178.
  45. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, et al: Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945–953.
    External Resources
  46. Sellon RK, Tonkonogy SL, Schultz M, Dieleman LA, Grenther WB, Balish E, et al: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224–5231.
    External Resources
  47. Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, et al: IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999;276:G1461–G1472.
  48. Rath HC, Wilson KH, Sartor RB: Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67:2969–2974.
    External Resources
  49. Kishi D, Takahashi I, Kai Y, Tamagawa H, Iijima H, Obunai S, et al: Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol 2000;165:5891–5899.
    External Resources
  50. Kim SC, Tonkonogy SL, Balish E, Sartor RB: IL-10 deficient mice monoassociated with non-pathogenic Enterococcus faecalis develop chronic colitis. Gastroenterology 2001;120:A441.
  51. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, et al: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277–2285.
    External Resources
  52. Dieleman LA, Hoentjen F, Ehre C, Mann BA, Sprengers D, Harmsen HJ, et al: Antibiotics with a selective aerobic and anaerobic spectrum have different therapeutic activities in various regions of the colon in IL-10 knock-out mice. Gastroenterology 2001;120:A687.
  53. Liu Y, Van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn’s disease. Gastroenterology 1995;108:1396–1404.
    External Resources
  54. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, et al: Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology 2000;119:23–31.
    External Resources
  55. Stimpson SA, Esser RE, Carter PB, Sartor RB, Cromartie WJ, Schwab JH: Lipopolysaccharide induces recurrence of arthritis in rat joints previously injured by peptidoglycan-polysaccharide. J Exp Med 1987;165:1688–1702.
    External Resources
  56. Lichtman SN, Keku J, Schwab JH, Sartor RB: Evidence for peptidoglycan absorption in rats with experimental small bowel bacterial overgrowth. Infect Immun 1991;59:555–562.
    External Resources
  57. Obermeier F, Dunger N, Deml L, Herfarth H, Schölmerich J: CpG motifs of bacterial DNA exacerbate colitis of dextran sodium-treated mice. Eur J Immunol 2002;32:2084–2092.
    External Resources
  58. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S: Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992;37:121–128.
    External Resources
  59. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al: Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol 1999;65:351–354.
    External Resources
  60. Marteau P, Pochart P, Bouhnik Y, Zidi S, Goderel I, Rambaud JC: Survival of Lactobacillus acidophilus and Bifidobacterium sp. in the small intestine following ingestion in fermented milk: A rational basis for the use of probiotics in man. Gastroenterol Clin Biol 1992;16:25–28.
    External Resources
  61. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC: Survival of bifidobacteria ingested via fermented milk during their passage through the human intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992;55:78–80.
    External Resources
  62. Drouault S, Corthier G, Ehrlich SD, Renault P: Survival, physiology, and lysis of Lactococcus lactis in the digestive tract. Appl Environ Microbiol 1999;65:4881–4886.
    External Resources
  63. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352–1355.
    External Resources
  64. Alander M, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A: Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. Lett Appl Microbiol 1997;24:361–364.
    External Resources
  65. Chauviére G, Coconnier M-H, Kernéis S, Fourniat J, Sevrin AL: Adhesion of Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Gen Microbiol 1992;138:1689–1696.
    External Resources
  66. Bernet MF, Brassart D, Neeser JR, Servin AL: Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachement and cell invasion by enterovirulent bacteria. Gut 1994;35:483–489.
    External Resources
  67. Elo S, Saxelin M, Salminen S: Attachement of Lactobacillus casei strain GG to human colon carcinoma cell line Caco-2: Comparison with other dairy strains. Lett Appl Microbiol 1991;13:154–156.
    External Resources
  68. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A: Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn’s disease. Infect Immun 1999;67:4499–4509.
    External Resources
  69. Ölschläger T, Altenhöfer A, Hacker J: Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic strain E. coli Nissle 1917. Gastroenterology 2001;120:A1682.
  70. Silva M, Jacobus NV, Deneke C, Gorbach SL: Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31:1231–1233.
    External Resources
  71. Meurman JH, Antila H, Korhonen A, Salminen S: Effect of Lactobacillus rhamnosus strain GG (ATCC 53103) on the growth of Streptococcus sobrinus in vitro. Eur J Oral Sci 1995;103:253–258.
    External Resources
  72. Hockertz S: Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. Arzneimittelforsch 1997;47:793–796.
  73. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA: Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941–G950.
  74. Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK: Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 2000;66:2578–2588.
    External Resources
  75. Shroff KE, Meslin K, Cebra JJ: Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 1995;63:3904–3913.
    External Resources
  76. Cebra JJ: Influences of microbiota on intestinal immune system development. Am J Clin Nutr 1999;69:1046S–1051S.
  77. Wold AE, Adlerberth I: Pathologic effects on commensialism; in Nataro JP, Blaser MJ, Cunningham-Rundles S (eds): Persistent Bacterial Infections. New York, ASM Publishing, 2000, pp 115–144.
  78. Kraehenbuhl J-P, Neutra MR: Epithelial M cells: Differentiation and function. Annu Rev Cell Dev Biol 2000;16:301–332.
    External Resources
  79. Wold AE: Immune effects of probiotics. Scand J Nutr 2001;45:76–85.
  80. Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde K, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934–938.
    External Resources
  81. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde K: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448–455.
    External Resources
  82. Sartor RB: Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 1994;106:533–539.
    External Resources
  83. Sartor RB: Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. Aliment Pharmacol Ther 1996;10:36–42.
    External Resources
  84. Powrie F, Mason D: OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 1990;172:1701–1708.
    External Resources
  85. Veltkamp C, Tonkonogy SL, De Jong YP, Albright C, Grenther WB, Balish E, et al: Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg(epsilon26) mice. Gastroenterology 2001;120:900–913.
    External Resources
  86. Rath HC, Ikeda JS, Linde HJ, Schölmerich J, Wilson KH, Sartor RB: Varying cecal bacterial loads influences colitis and gastritis in HLA- B27 transgenic rats. Gastroenterology 1999;116:310–319.
    External Resources
  87. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK: Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996;184:707–715.
    External Resources
  88. Ulisse S, Gionchetti P, D’Alò SD, Russo FP, Pesce I, Ricci G, et al: Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinase in pouchitis: Effects of probiotic treatment. Am J Gastroenterol 2001;96:2691–2699.
    External Resources
  89. Helwig U, Rizzello F, Waterworth C, Zucchoni E., Venturi A: Effect of probiotic therapy on pro- and antiinflammatory cytokines in pouchitis. Gut 1999;45:A01.04.
    External Resources
  90. Schultz M, Veltkamp C, Dieleman LA, Wyrick RB, Tonkongy SL, Sartor RB. Lactobacillus plantarum 299v in treatment and prevention of spontaneous colitis in IL-10-deficient mice. Inflamm Bowel Dis 2002;8:71–80.
    External Resources
  91. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S: Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 2000;47:79–87.
    External Resources
  92. Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ: Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun 2000;68:752–759.
    External Resources
  93. Miettinen M, Vuopio-Varkila J, Varkila K: Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996;64:5403–5405.
    External Resources
  94. Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, et al: Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun 1998;66:6058–6062.
    External Resources
  95. Miettinen M, Lehtonen A, Julkunen I, Matikainen S: Lactobacilli and streptococci activate NF-kappa B and STAT signaling pathways in human macrophages. J Immunol 2000;164:3733–3740.
    External Resources
  96. Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, et al: Effect of probiotic strains on interleukin-8 production by HT-29/19A cells. Am J Gastroenterol 2002;97:1182–1186.
    External Resources
  97. Tejada-Simon MV, Ustunol Z, Pestka JJ: Effects of lactic acid bacteria ingestion on basal cytokine mRNA and immunoglobulin levels in the mouse. J Food Prot 1999;52:287–291.
  98. Brandzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, et al: Immunobiology and immunopathology of human gut mucosa: Humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989;97:1562–1584.
    External Resources
  99. Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N: Immune system stimulation by probiotics. J Dairy Sci 1995;78:1597–1606.
    External Resources
  100. Perdigon G, Alvarez S, Pesce de Ruiz HA: Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections. J Dairy Res 1991;58:485–496.
    External Resources
  101. Malin M, Suomalainen H, Saxelin M, Isolauri E: Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metabol 1996;40:137–145.
    External Resources
  102. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H: Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992;32:141–144.
    External Resources
  103. Delneste Y, Donnet-Hughes A, Schiffrin EJ: Functional Foods: Mechanisms of action on immunocompetent cells. Nutr Rev 1998;56:S93–S98.
  104. DeSimone C, Vesley R, Bianchi Salvadori B, Jirillo E: The role of probiotics in modulation of the immune system in man and in animals. Int J Immunother 1993;9:23–28.
  105. McNab R, Tannock GW, Jenkinson HF: Characterization of CshA, a high molecular mass adhesin of Streptococcus gordonii. Dev Biol Stand 1995;85:371–375.
    External Resources
  106. Schultz M, Linde HJ, Lehn N, Zimmermann K, Grossmann J, Falk W et al: Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG (L. GG) in healthy volunteers. J Dairy Res 2003;70:163–170.
  107. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A: Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995;78:491–497.
    External Resources
  108. Neish AS, Gewirtz AT, Zeng H, Young AF, Hobert ME, Karmali V, et al: Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science 2000;289:1560–1563.
    External Resources
  109. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, et al: Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991;338:771–774.
    External Resources
  110. D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262–267.
    External Resources
  111. Duchmann R, Marker-Hermann E, Meyer zum Büschenfelde K: Bacteria-specific T-cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease. Scand J Immunol 1996;44:71–79.
    External Resources
  112. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365–375.
    External Resources
  113. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E: Metronidazole in Crohn’s disease: A double blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123–127.
    External Resources
  114. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, et al: A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: The cooperative Crohn’s disease study in Sweden. Gastroenterology 1982;83:550–562.
    External Resources
  115. Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn’s disease activity index. Gastroenteology 1976;70:139–144.
  116. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, et al: Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–1075.
    External Resources
  117. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995;108:1617–1621.
    External Resources
  118. Bradley WG, Karlsson IJ, Rassol CG: Metronidazole neuropathy. Br Med J 1977;ii:610–611.
  119. Duffy LF, Daum F, Fisher SE, Selman J, Vishnubhakat SM, Aiges HW, et al: Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 1985;88:681–684.
    External Resources
  120. Rutgeerts PJ, D’Haens G, Baert F, Sels F, Hiele M, Aerden I, et al: Nitromidazol antibiotics are efficacious for prophylaxis of postoperative recurrence of Crohn’s disease: a placebo-controlled trial. Gastroenterology 1999;116:G3506.
  121. Triantafillidis JK, Nicolakis D, Emmanoullidis A, Antoniou A, Papatheodorou K, Cheracakis P: Ornidazole in the treatment of active Crohn’s disease: Short-term results. Ital J Gastroenterol 1996;28:10–14.
    External Resources
  122. Madden MV, McIntyre AS, Nicholls RJ: Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193–1196.
    External Resources
  123. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F: Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497–500.
    External Resources
  124. Turunen UM, Farkkila MA, Hakala K, Seppaia K, Sivonen A, Ogren M, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072–1078.
    External Resources
  125. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971–974.
    External Resources
  126. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, et al: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674–678.
    External Resources
  127. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, et al: An antibiotic regimen for the treatment of active Crohn’s disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–332.
    External Resources
  128. Prantera C, Berto E, Scribano ML, Falasco G: Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998;30:602–606.
    External Resources
  129. Greenbloom SL, Steinhart AH, Greenberg GR: Combination of ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol 1998;12:53–56.
    External Resources
  130. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, et al: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Therap 1999;13:713–718.
    External Resources
  131. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C: Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513–518.
    External Resources
  132. Dalziel TK: Chronic intestinal enteritis. Br Med J 1913;ii:1068–73.
  133. Kanazawa K, Haga Y, Funakoshi O, Nakajima H, Munakata A, Yoshida Y: Absence of Mycobacterium paratuberculosis DNA in intestinal tissues from Crohn’s disease by nested polymerase chain reaction. J Gastroenterol 1999;34:200–206.
    External Resources
  134. Kreuzpaintner G, Das PK, Stronkhorst A, Slob AW, Strohmeyer G: Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn’s disease. Gut 1995;37:361–366.
    External Resources
  135. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA: Controlled trial of rifampicin and ethambutol in Crohn’s disease. Gut 1984;25:203–205.
    External Resources
  136. Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, et al: Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut 1994;35:363–368.
    External Resources
  137. Thomas GA, Swift GL, Green JT, Newcombe RG, Braniff-Mathews C, Rhodes J, et al: Controlled trial of antituberculous chemotherapy in Crohn’s disease: A five year follow up study. Gut 1998;42:497–500.
    External Resources
  138. Graham DY, Al-Assi MT, Robinson M: Prolonged remission in Crohn’s disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995;108:A826.
  139. Goodgame RW, Kimball K, Akram S, Graham DY, Ou CN: Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn’s disease. Gastroenterology 1999;116:A725.
  140. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263–274.
    External Resources
  141. Madsen KL, Doyle JS, Jewell LD, Taverini MM, Fedorak RN: Lactobacillus species prevents colitis in Interleukin-10 gene-deficient mice. Gastroenterology 1999;116:1107–1114.
    External Resources
  142. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al: Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370–376.
    External Resources
  143. Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al: Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8:399–406.
    External Resources
  144. Schultz M, Melchner I, Schwietz H, Schölmerich J, Rath HC: A new pre- and probiotic preparation attenuates colitis in HLA-B27 transgenic mice. Gastroenterology 2002;116:A391.
    External Resources
  145. Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G, et al: The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology 1996;111:334–344.
    External Resources
  146. Holma R, Salmenperä P, Lohi J, Vapaatalo H, Korpela R: Effects of Lactobacillus rhamnosus GG and Lactobacillus reuteri R2LC on acetic acid-induced colitis in rats. Scand J Gastroenterol 2001;6:630–635.
    External Resources
  147. Schultz M, Sartor RB: Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000;95:S19-S21.
    External Resources
  148. Shanahan F: Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 2000;6:107–115.
    External Resources
  149. Shanahan F: Therapeutic manipulation of gut flora. Science 2000;289:1311–1312.
    External Resources
  150. Dunne C: Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 2001;7:136–145.
    External Resources
  151. Saxelin M: Lactobacillus GG: A human probiotic strain with thorough clinical documantation. Food Rev Int 1997;13:293–313.
  152. Gorbach SL, Chang TW, Goldin BR: Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987;26:1519.
  153. Oksanen P, Salminen S, Saxelin M, Hämäläinen P, Ihantola-Vormisto A, Muurasniemi-Isoviita L, et al: Prevention of traveller’s diarrhea by Lactobacillus GG. Ann Med 1990;22:53–56.
    External Resources
  154. Hilton E, Kolakowski P, Smith M, Singer C: Efficacy of Lactobacillus GG as a diarrheal preventative in travelers. J Travel Med 1997;4:41–43.
    External Resources
  155. Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach SL: Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995;21:224–226.
    External Resources
  156. Cremonini F, Di Caro S, Nista EC, Bartolozzi F, Capelli G, Gasbarrini G, et al: Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002;16:1461–1467.
    External Resources
  157. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E: Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 2001;8:293–296.
    External Resources
  158. Isolauri E: The use of probiotics in paediatrics. Hosp Med 2000;61:6–7.
    External Resources
  159. Vanderhoof JA. Probiotics and intestinal inflammatory disorders in infants and children. J Pediatr Gastroenterol Nutr 2000;30:S34-S38.
    External Resources
  160. Gupta P, Andrew H, Kirschner BS, Guandalini S: Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453–457.
    External Resources
  161. Friedman G, George J: Treatment of refractory ‘pouchitis’ with prebiotic and probiotic therapy. Gastroenteology 2000;118:A4167.
  162. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: A randomised controlled trial with Lactobacillus GG. Gut 2002;51:405–409.
    External Resources
  163. Nissle A: On the clarification of the relations of disease cause, symptoms and rational therapy. Med Welt 1966;23:1290–1294.
    External Resources
  164. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853–858.
    External Resources
  165. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–639.
    External Resources
  166. Kruis W, Fric P, Stolte M: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 2001;120:A680.
  167. Malchow HA: Crohn’s disease and Escherichia coli: A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997;25:653–658.
    External Resources
  168. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G: Prevention of antibiotica-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterology 1989;96:981–988.
    External Resources
  169. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al: The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin with Saccharomyces boulardii. CID 2000;31:1012–1017.
  170. Pein K, Hotz J: Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea: A pilot study. Z Gastroenterol 1993;31:129–134.
    External Resources
  171. Guslandi M: Saccharomyces boulardii in the maintenance of Crohn’s disease. Can J Gastroenterol 2000;14:32.
    External Resources
  172. Liao W, Cui XS, Jin XY, Floren CH: Lactulose: A potential drug for the treatment of IBD. Med Hypotheses 1994;43:234–238.
    External Resources
  173. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al: Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003;124:1204–1209.
  174. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, et al: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: A randomized controlled study vs. mesalamine. Gastroenterology 2000;118:A4179.
  175. Kanauchi O, Nakamura T, Agata K, Mitsuyama K, Iwanaga T: Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J Gastroenterol 1998;33:179–188.
    External Resources
  176. Kanauchi O, Andoh A, Araki Y, Mitsuyama K, Toyonaga A, Sata S, et al: The mechanism of germinated barley foodstuff in attenuating intestinal inflammation in colitis. Gastroenterology 2000;118:A73.
  177. Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, et al: Treatment of ulcerative colitis with germinated barley foodstuff feeding: A pilot study. Aliment Pharmacol Ther 1998;12:1225–1230.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Review Article

Published online: October 24, 2003
Issue release date: 2003

Number of Print Pages: 24
Number of Figures: 3
Number of Tables: 2

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2003, Vol.21, No. 2

2003

Article

Recommend This
TOP